Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04202354 |
Recruitment Status :
Completed
First Posted : December 17, 2019
Last Update Posted : December 6, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-alcoholic Steatohepatitis | Drug: ARO-HSD Injection Drug: sterile normal saline (0.9% NaCl) | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2a Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-HSD in Normal Healthy Volunteers as Well as in Patients With NASH or Suspected NASH |
Actual Study Start Date : | March 3, 2020 |
Actual Primary Completion Date : | September 3, 2021 |
Actual Study Completion Date : | November 23, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: ARO-HSD |
Drug: ARO-HSD Injection
single or multiple doses of ARO-HSD by subcutaneous (sc) injections |
Placebo Comparator: Placebo |
Drug: sterile normal saline (0.9% NaCl)
calculated volume to match active treatment, by sc injection |
- Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment [ Time Frame: single dose phase: Up to 113 (+/-2 days) post-dose; multiple dose phase: (Up to 196 (+/- 14 days) post-dose for patients with NASH ]
- PK of ARO-HSD: Maximum observed Plasma Concentration (Cmax) [ Time Frame: Up through Day 29 after a single dose ]
- PK of ARO-HSD: Time to Maximum Plasma Concentration (Tmax) [ Time Frame: Up through Day 29 after a single dose ]
- PK of ARO-HSD: Terminal Elimination Half-Life (t1/2) [ Time Frame: Up through Day 29 after a single dose ]
- PK of ARO-HSD: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24) [ Time Frame: Up through Day 29 after a single dose ]
- PK of ARO-HSD: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUCinf) [ Time Frame: Up through Day 29 after a single dose ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception
- Willing to provide written informed consent and to comply with study requirements
- On a stable diet for at least 4 weeks with no plans to significantly alter diet or weight over course of study
- Normal electrocardiogram (ECG) at Screening
- No abnormal finding of clinical relevance (other than NASH, suspected NASH in patients) at Screening that could adversely impact subject safety during the study or adversely impact study results.
Exclusion Criteria:
- Clinically significant health concerns (other than NASH, suspected NASH in patients)
- Human immunodeficiency virus (HIV) infection, seropositive for Hepatitis B Virus (HBV), seropositive for Hepatitis C Virus (HCV)
- Uncontrolled hypertension
- Excessive use of alcohol within three months prior to Screening
- Use of illicit drugs within 1 year prior to Screening, or positive urine drug screen at Screening
- Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study
NOTE: additional inclusion/exclusion criteria may apply, per protocol
-
-
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04202354
New Zealand | |
Auckland Clinical Studies | |
Grafton, Auckland, New Zealand, 1010 |
Responsible Party: | Arrowhead Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT04202354 |
Other Study ID Numbers: |
AROHSD1001 |
First Posted: | December 17, 2019 Key Record Dates |
Last Update Posted: | December 6, 2021 |
Last Verified: | December 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Fatty Liver Non-alcoholic Fatty Liver Disease Liver Diseases Digestive System Diseases |